The global spatial genomics and transcriptomics market size was valued at USD 163.8 million in 2020 and is expected to expand at a CAGR of 11.1% from 2021 to 2028. Architecture analysis of genome content in histological specimens is considered a cornerstone in several biomedical research and diagnostics. This is effectively addressed by the advent of spatial omics as a technology-driven field that involves the determination of high-throughput omics data procured from tissue and cell specimens, along with data for the organizational structure of cell content, resulting in the revenue growth of the market. Technologies being introduced in this market are a result of convergence between conventional imaging technologies and novel high-throughput sequencing technologies with methods that help determine positional information of DNAs and RNAs. Although this field holds significant potential in disease management, spatially resolved omics need better implementation for the development of new methods to boost the market growth.
Moreover, key market players are focused on expanding their spatial transcriptomics and genomics footprints by entering into strategic partnerships and collaborations with other players. Moreover, the companies are undertaking strategies to expand their customer base across the globe. For instance, in February 2020, Dovetail Genomics announced the global availability of its Dovetail HiChIP and Micro-C Kits.
Dovetail Micro-C kits provide a better resolution of chromatin contacts at a mononucleosome level, whereas HiChIP technology combines the Micro-C and ChIP-seq into one workflow, which allows assaying protein-directed alterations to chromatin architecture, enabling assessment of its impact on gene expression.
The onset of COVID-19 has partially offset the revenue growth of operating market players. However, NanoString’s GeoMx Digital Spatial Profiling accelerates SARS-CoV-2 research as it is well established to operate using FFPE samples—specimens that are being provided by COVID-19 autopsies. Thus, the current global pandemic has created considerable opportunities for the market players operating in the space.
The spatial transcriptomics segment dominated the market with a revenue share of 82.2% in 2020 owing to its high adoption as compared to spatial genomic methods for the transcriptomic study of single cells. The growth of this segment can also be attributed to the availability of automated sequencing methodologies, such as laser capture microdissection technique (LCM), to meet the expanding demand for nucleic acid sequencing of biological specimens or single cells.
Sequencing of a nucleic acid of single cells or specific biological specimens has increased, which has driven the need for automated, robust, and scalable library preparation solutions. Furthermore, an increased understanding of tissue heterogeneity has resulted in the launch of several unique sequencing workflows that are aimed at inferring or preserving the spatial information. This has also accelerated the revenue flow in this segment.
The determination of spatial arrangement of molecules in cells and tissue samples is the basis for biological research and clinical practice and has gained the attention of several entities involved in the field of genetics. Furthermore, advancements in genome perturbation tools, like the CRISPR/Cas9 system, aid the adoption of spatial genomic tools, thereby driving the segment.
The consumables segment dominated the market with a share of 53.0% in 2020 as this segment covers products that are required to run the instruments across various stages of genome mapping from sample preparation to result derivation. High product penetration, wide product availability, frequent purchase of consumables, and increased usage rate of reagents and kits to run the instruments have driven revenue flow in this segment. The development of any new instrument or upgrade of any existing instrument has a direct impact on the segment growth as the development of any new instrument will result in the need for developing the required consumables.
The software segment is anticipated to grow lucratively throughout the forecast period. The increasing volume of ongoing genomic research studies has led to the need for robust software solutions for data management and their interpretation. This is anticipated to drive the segment in the coming years. Furthermore, companies are expanding their service offerings to stay competitive in the space. For instance, in January 2020, Dovetail Genomics expanded its Genome Assembly offerings to include annotations and chromosome-scale assemblies and 3D genome conformation analysis. The company leveraged on its Omni-C Technology to expand its genome assembly services.
The academic customers' segment captured the largest revenue share of 59.3% in 2020. This is because spatial genomic analyses are increasingly being employed in academic research institutions as they provide a comprehensive analysis of various disorders. For instance, the research institute at Children’s Hospital of Philadelphia has installed a Center of Spatial and Functional Genomics to study the genetic basis of several common disorders with the help of 3D Genomics-based techniques.
Spatial genomics and transcriptomics have enabled the researchers of the universities to explore new areas in gene expression dynamics. The technology finds applications in large research projects, such as the Human Cell Atlas, and is useful for academic researchers involved in the study of the morphological state of cells for genetically derived diseases, such as cancer, diabetes, and Alzheimer’s.
The translational research end-use segment held a major share in 2020 as the use of spatial omics technologies in translational research may potentially benefit research by providing a thorough analysis of physiology and state of a disease, which further propels the introduction of new diagnostic tools and therapeutics. Considering these potential benefits, key players are involved in the research and development of predictive and pharmacogenetic tests that help in the early diagnosis of critical disorders.
North America accounted for the largest revenue share of 44.8% in 2020. This is attributed to the strategic investments in disease pathology research and the increased focus on transcriptomics R&D. For instance, the ongoing Single Cell Analysis Program by the National Institutes of Health Common Fund, initiated in 2012, focuses on sequencing approaches and improvement of spatial resolution through fluorescence-based techniques.
Asia Pacific is anticipated to grow at a lucrative rate during the forecast period. The international collaboration and partnership between Asian research institutes and global companies to propel the usage of technologies across Asian countries are driving the revenue in this region. For instance, in February 2020, the RIKEN Center for Integrative Medical Sciences (IMS) joined the S2 Genomics Early Technology Access Program to assess and establish single-cell sequencing applications on the Singulator tissue preparation system by S2 Genomics. This initiative evaluated the system’s performance and developed a new range of applications for the company’s platform.
Market players are engaged in introducing novel solutions with a competitive advantage to enhance their market position in the coming years. For instance, in February 2020, ReadCoor, Inc. introduced its first product line that includes the RC2 instrument and multi-omic spatial sequencing assays. The instrument deploys the Fluorescent In Situ Sequencing (FISSEQ) technology of the company to operate. Some prominent players in the global spatial genomics and transcriptomics market include:
Natera Inc.
10x Genomics
Dovetail Genomics
Illumina, Inc.
S2 Genomics, Inc.
NanoString Technologies, Inc.
Seven Bridges Genomics
Horizon Discovery Group plc
CARTANA AB
READCOOR, INC.
Bio-Techne
Report Attribute |
Details |
Market size value in 2021 |
USD 194.9 million |
Revenue forecast in 2028 |
USD 381.3 million |
Growth Rate |
CAGR of 11.1% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD thousand/million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Technology, product, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Spain; Italy; Netherlands; Japan; China; India; South Korea; Australia; Singapore; Brazil; South Africa |
Key companies profiled |
Natera Inc.; 10x Genomics; Dovetail Genomics; Illumina, Inc.; S2 Genomics, Inc.; NanoString Technologies, Inc.; Seven Bridges Genomics; Horizon Discovery Group plc; CARTANA AB; READCOOR, INC.; Bio-Techne |
Customization scope |
Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global spatial genomics and transcriptomics market report on the basis of technology, product, end-use, and region:
Technology Outlook (Revenue, USD Thousand, 2017 - 2028)
Spatial Transcriptomics
Sequencing-based Methods
Laser Capture Microdissection (LCM)
FFPE Tissue Samples
Others
Transcriptome In-vivo Analysis (TIVA)
In Situ Sequencing
Microtomy Sequencing
IHC
Microscopy-based RNA Imaging Techniques
Single Molecule RNA Fluorescence In-situ Hybridization (smFISH)
Padlock Probes/ Rolling Circle Amplification
Branched DNA Probes
Spatial Genomics
FISH
Microscopy-based Live DNA Imaging
Genome Perturbation Tools
Massively-parallel Sequencing
Biochemical Techniques
Others
Product Outlook (Revenue, USD Thousand, 2017 - 2028)
Instruments
By Mode
Automated
Semi-automated
Manual
By Type
Sequencing Platforms
IHC
Microscopy
Flow Cytometry
Mass Spectrometry
Others
Consumables
Software
Bioinformatics Tools
Imaging Tools
Storage and Management Databases
End-use Outlook (Revenue, USD Thousand, 2017 - 2028)
Translational Research
Academic Customers
Diagnostic Customers
Pharmaceutical Manufacturer
Regional Outlook (Revenue, USD Thousand, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Netherlands
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Latin America
Brazil
Middle East and Africa (MEA)
South Africa
b. The global spatial genomics & transcriptomics market size was estimated at USD 163.8 million in 2020 and is expected to reach USD 194.9 million in 2021.
b. The global spatial genomics & transcriptomics market is expected to grow at a compound annual growth rate of 11.1% from 2021 to 2028 to reach USD 381.3 million by 2028.
b. Spatial transcriptomics dominated the spatial genomics & transcriptomics market with a share of 82% in 2020 owing to the wide-scale implementation of spatial transcriptomic sequencing methods for the transcriptomic profiling of single cells.
b. Some key players operating in the spatial genomics & transcriptomics market include 10x Genomics; Dovetail Genomics; Illumina, Inc.; S2 Genomics, Inc.; NanoString Technologies; Seven Bridges Genomic; Horizon Discovery Group plc; CARTANA AB; and Advanced Cell Diagnostics.
b. Key factors that are driving the market growth include the emergence of the fourth generation of sequencing and the increasing demand for robust and early diagnostics in cancer management.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.